10 Stocks Under $10 that Will Triple

5. Gossamer Bio, Inc. (NASDAQ:GOSS)

Upside Potential: 457.52%

Number Of Hedge Funds: 35

Gossamer Bio, Inc. (NASDAQ:GOSS) develops targeted treatments for pulmonary arterial hypertension (PAH) and other serious conditions. This clinical-stage biotech company has its leading drug candidate in Phase 3 trials for PAH, with further studies expected to launch in 2025. The company is also growing its pipeline in immunology, inflammation, and cancer research.

Gossamer Bio, Inc. (NASDAQ:GOSS) cut its quarterly losses to $33 million ($0.15 per share) for Q4, beating the expectation of a $0.17 loss. This 11.76% earnings surprise shows a significantly improved performance from the company’s $48.1 million loss in the same quarter last year. For 2024, losses were reduced to $56.5 million from $179.8 million in 2023 due to efficient cost controls. Meanwhile, revenue hit $9.38 million in Q4, beating estimates by 19.63% compared to zero revenue generation a year earlier. As such, Gossamer’s cash reserves stood at $294.5 million as of the year-end, which management believes should sufficiently fund operations until 2027.

Furthermore, Gossamer Bio, Inc. (NASDAQ:GOSS) continues advancing its late-stage clinical work with key results from its PAH study expected to arrive in 2025. The company is also getting ready for possible regulatory submission with progress in other pipeline programs, supporting its growth outlook. Also, hedge funds are now bullish on the stock because of its promising pipeline.

Gossamer Bio, Inc. (NASDAQ:GOSS) stands out among the list of stocks under $10 that will triple. Thus, its clinical progress and strong financial standing make it an attractive small-cap investment option.